|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.93 CNY | -1.89% |
|
-0.82% | -8.46% |
| 07-18 | Shyndec Pharmaceutical's H1 Profit Slips 7%, Total Revenue Drops 18% | MT |
| 07-17 | Shanghai Shyndec Pharmaceutical prelim H1 net profit down 6.5% Y/Y | RE |
Projected Income Statement: Shanghai Shyndec Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 12,070 | 10,938 | 12,040 | 12,642 |
| Change | - | - | -9.38% | 10.08% | 5% |
| EBITDA | - | - | 2,418 | - | - |
| Change | - | - | - | - | - |
| EBIT | - | - | 1,752 | - | - |
| Change | - | - | - | - | - |
| Interest Paid | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | 1,673 | - | - |
| Change | - | - | - | - | - |
| Net income 1 | 626.6 | 691.9 | 1,084 | 1,202 | 1,351 |
| Change | - | 10.42% | 56.62% | 10.92% | 12.4% |
| Announcement Date | 1/13/23 | 3/29/24 | 3/27/25 | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Shanghai Shyndec Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Change | - | - | - | - | - |
| Announcement Date | 1/13/23 | 3/29/24 | 3/27/25 | - | - |
Estimates
Cash Flow Forecast: Shanghai Shyndec Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 403.8 | 378 | 521.4 | 307.4 | 357.2 | 219.8 |
| Change | - | -6.4% | 37.96% | -41.04% | 16.18% | -38.47% |
| Free Cash Flow (FCF) 1 | -331.8 | -101 | 621.9 | 1,634 | 1,796 | 1,668 |
| Change | - | 69.55% | 715.5% | 162.68% | 9.96% | -7.13% |
| Announcement Date | 4/1/20 | 3/25/21 | 3/25/22 | 3/29/23 | 3/29/24 | 3/27/25 |
1CNY in Million
Estimates
Forecast Financial Ratios: Shanghai Shyndec Pharmaceutical Co., Ltd.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | - | - | - | 22.11% | - | - |
| EBIT Margin (%) | - | - | - | - | - | 16.02% | - | - |
| EBT Margin (%) | - | - | - | - | - | 15.3% | - | - |
| Net margin (%) | - | - | - | - | 5.73% | 9.91% | 9.98% | 10.69% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | - | - | - | 3.55% | 5.51% | 6.1% | 6.4% |
| ROE | - | - | - | - | 6.02% | 8.45% | 9.1% | 9.9% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | 0.05x | - | - | - | - | - | - |
| Debt / Free cash flow | - | -0.86x | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | 1.81% | - | - |
| CAPEX / EBITDA (%) | - | - | - | - | - | 8.18% | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | 1.283 | 1.682 | 1.19 | 1.33 |
| Change | - | - | - | - | - | 31.14% | -29.26% | 11.76% |
| Dividend per Share 1 | - | - | - | - | 0.1 | 0.2 | 0.224 | 0.252 |
| Change | - | - | - | - | - | 100% | 12% | 12.5% |
| Book Value Per Share 1 | - | - | - | - | 9.237 | 9.845 | 9.96 | 10.35 |
| Change | - | - | - | - | - | 6.58% | 1.17% | 3.92% |
| EPS 1 | - | - | - | 0.6101 | 0.5433 | 0.808 | 0.9 | 1.01 |
| Change | - | - | - | - | -10.95% | 48.72% | 11.39% | 12.22% |
| Nbr of stocks (in thousands) | - | - | - | 1,026,983 | 1,341,173 | 1,341,173 | 1,341,173 | 1,341,173 |
| Announcement Date | - | - | - | 1/13/23 | 3/29/24 | 3/27/25 | - | - |
1CNY
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | 12.1x | 10.8x |
| PBR | 1.1x | 1.06x |
| EV / Sales | 1.22x | 1.16x |
| Yield | 2.05% | 2.31% |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10.93
Average target price
-
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600420 Stock
- Financials Shanghai Shyndec Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition